Analyst firms · HSBC · GILD
HSBC GILD price target and rating history
Gilead Sciences Inc. (GILD) · Health Care
HSBC rates Gilead Sciences Inc. (GILD) Buy with a $155 price target, as of its latest action on Jul 6, 2026. It has published 3 rating actions on GILD since September 2023, including 2 upgrades and 0 downgrades. Across 9 firms with a GILD price target in the last 12 months, the median target is $155. HSBC's target matches it.
- Current rating
- Buy
- Price target
- $155
- Median target, all firms
- $155
- Actions on GILD
- 3
HSBC price target on GILD
Every HSBC rating on GILD
- Jul 6, 2026
- Apr 24, 2024
- Sep 6, 2023
How other firms rate GILD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Market Perform | $127 | Jul 21, 2026 |
| HSBC | Buy | $155 | Jul 6, 2026 |
| Maxim Group | Buy | $165 | May 20, 2026 |
| Jefferies | Buy | $180 | Mar 10, 2026 |
| Barclays | Equal Weight | $155 | Feb 20, 2026 |
| Needham | Buy | $170 | Feb 11, 2026 |
| UBS | Buy | $145 | Jan 7, 2026 |
| Truist Securities | Buy | $140 | Nov 24, 2025 |
| Scotiabank | Sector Outperform | $140 | Nov 13, 2025 |
Questions about HSBC and GILD
- What is HSBC's price target for GILD?
- HSBC's latest stated price target for Gilead Sciences Inc. (GILD) is $155, from its action on Jul 6, 2026.
- What is HSBC's rating on GILD?
- HSBC rates GILD Buy, a bullish rating, as of Jul 6, 2026.
- When did HSBC last change its view on GILD?
- On Jul 6, 2026, HSBC upgrades to Buy from Hold, price target $155.
- How does HSBC's GILD target compare with other analysts?
- Across 9 firms with a GILD price target in the last 12 months, the median target is $155. HSBC's target matches it.
More GILD rating histories
- Leerink Partners5
- Maxim Group3
- Barclays4
- Truist Securities5
- Morgan Stanley5
- BofA Securities4
- Wells Fargo4
- BMO Capital Markets6
- Piper Sandler3
- RBC Capital Markets5
All HSBC ratingsGILD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.